Off-pump or minimized on-pump coronary surgery - initial experience with Circulating Endothelial Cells (CEC) as a supersensitive marker of tissue damage by Wittwer, Thorsten et al.
RESEARCH ARTICLE Open Access
Off-pump or minimized on-pump coronary
surgery - initial experience with Circulating











Background: Off-pump-coronary-artery-bypass-grafting (OPCAB) and minimized-extracorporeal-circulation (Mini-
HLM) have been proposed to avoid harmful effects of cardiopulmonary-bypass (CPB). Controversies exist whether
OPCAB is still superior in perioperative outcome. Circulating endothelial cells (CEC) are sensitive markers of
endothelial damage and are significantly elevated in conventional-CPB-procedures as compared to Mini-HLM-
revascularisation. Therefore, CEC might be of specific value in evaluating effectiveness of Mini-HLM and OPCAB as
currently applied less-invasive coronary procedures.
Methods: 76 coronary patients were randomly assigned either to OPCAB (n = 34) or to Mini-HLM (ROCsafe™,
Terumo Inc., n = 42) procedures. Perioperative data, clinical and serological outcome and measurements of CEC-
release and parameters of endothelial function (v.Willebrand-Factor, soluble-thrombomodulin) perioperatively (pre-
operative-baseline, post-Mini-HLM/release of OPCAB-stabilizer, 6 h, 12 h, 24 h and 5 days postoperatively) were
obtained and compared by ANOVA models including repeated-measures-analysis.
Results: Mean graft-number was 3.06 ± 0.72 in Mini-HLM-patients and 1.89 ± 0.74 in OPCAB-patients (p < 0.001).
However, ventilation-, ICU- and total-hospital duration were comparable between groups as well as chest-tube-
drainage, transfusion requirements, hemodynamics and catecholaminergic support (p > 0.05). CEC-release did not
differ between groups (p = 0.274) and was generally within normal limits, Troponin-T levels where not significanty
different (p = 0.108). No myocardial infarctions, strokes or deaths occurred, neuron specific enolase (NSE) did not
show any differences between groups (p = 0.194).
Conclusion: Conceptional advantages of minimized CPB systems (ROCsafe™) result in morbidity and mortality
comparable with OPCAB procedures. Mini-HLM therefore minimizes CPB-related systemic and organ injury as
demonstrated by low CEC-values which indicates intact endothelial integrity. Furthermore, Mini-HLM combines
OPCAB-benefits with low morbidity in high-risk patients while facilitating more complete revascularization in
complex patients.
Keywords: Minimal Invassive Cardiac Surgery, Minimised Extracorporeal circulation, OPCAB, Circulating endothelial
cells
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For decades coronary artery bypass grafting (CABG) was
performed with the use of conventional cardiopulmon-
ary bypass (CCPB). However, CCPB has been considered
to be a potent stimulus of a generalized inflammatory
state and thus having the potential to result in signifi-
cant morbidity [1]. In order to decrease morbidity and
mortality associated with coronary surgery, myocardial
revascularization without CCPB has been introduced
into clinical practice in terms of the off-pump coronary
artery bypass grafting (OPCAB) procedure [2]. A num-
ber of randomized controlled studies comparing
OPCAB to CCPB have been completed since then.
Although outcomes have been largely comparable, the
evidence of benefit of OPCAB has not been as convin-
cing as primarily anticipated [3]. Technically, OPCAB
revascularisation can be very demanding, particularly
when marginal branches need to be revascularized
which may result in severe hemodynamic instability due
to cardiac displacement [4]. Therefore, initial enthu-
siasm for OPCAB became especially tempered by con-
cern about the completeness of revascularization, the
rate of perioperative myocardial infaction and long-term
graft patency rates [5,6]. As a consequence, minimized
extracorporeal circulation systems (Mini-HLM) have
been proposed to avoid the potentially harmful effects
of CCPB. The basic idea of Mini-HLM is to ensure ade-
quate perfusion by a closed, extremely minimized circuit
based on a rotary blood pump and a high-performance
membrane oxygenator with elimination of blood-to-air
contact by avoiding a venous reservoir, minimizing
hemodilution and mechanical blood trauma and signifi-
cant reduction of contact activation by reduced foreign
surfaces [7]. Meanwhile, a clear superiority of Mini-
HLM systems could be proven when compared to con-
ventional CPB circuits [8]. Among the different available
minimized systems, the ROCSafe™ systems (Terumo
Medical Corp., Somerset, NJ, USA) is associated with
superior de-airing, is suitable for both coronary and aor-
tic valve surgery and was shown to improve postopera-
tive recovery, reduce early inflammatory response,
transfusion requirements and atrial fibrillation [9,10].
One major mechanism of the beneficial effect of Mini-
HLM is considered to be the lesser degree of endothelial
injury which can be specifically assessed by quantifica-
tion of Circulating Endothelial Cells (CEC) which repre-
sent a novel marker of the intrinsic endothelial damage
caused by cardiopulmonary bypass [11]. Detachment of
endothelial cells into the blood stream represents a ser-
ious injury of the endothelium as one of multiple severe
adverse effects of CCPB [1,11]. As quantification of CEC
can unveil both endothelial damage and correlate with
activity as well as degree of injury at early preclinical
stages [12,13], the combined approach of CEC quantifi-
cation and cardiac Troponin measurement may signifi-
cantly improve the diagnostic accuracy in evaluation of
different coronary revascularization procedures in ana-
logy to findings in NSTEMI-patients [11,14]. As there
are still very few studies available comparing the mod-
ern less invasive surgical procedures Mini-HLM- with
OPCAB-revascularization [15], it was the aim of our
present study to directly compare both currently applied
surgical revascularization procedures with special regard
to the corresponding kinetics of perioperative CEC




This prospective randomized ethics approved clinical
trial was performed between July 2009 and January 2010
at our institution. Included were a total of 76 stable cor-
onary patients (age > 18 years) according to the follow-
ing criteria: all patients were scheduled for elective
isolated myocardial revascularization performed via full
median sternotomy and had been judged technically sui-
table for both OPCAB and Mini-HLM techniques. Indi-
cation for coronary surgery was established on the basis
of current international guidelines [16]. Patients with
unstable angina, myocardial infarction preoperative
proinflammatory status, insulin-dependent diabetes or
inflammatory vascular diseases were excluded from this
study as CEC-values are known to be elevated in all
these instances [17]. After inclusion, all patients were
randomized according to a computer-generated algo-
rithm either to the OPCAB or the Mini-HLM-proce-
dure. The institutional ethics committee approved this
study, and all patients gave informed written consent
prior to entering the study.
2. Analysis of CEC frequency
CEC frequency in the peripheral blood was determined
as described previously [11] with minor modifications
(Figure 1). Briefly, arterial blood samples were collected
in 2,7 ml EDTA tubes (Sarstedt, Nümbrecht, Germany),
and stored at 4°C for a maximum of 24 h for later batch
analysis. The monoclonal mouse anti-human CD146
antibody (clone S-Endo1/F4-35H7, Biocytex, Marseille,
France) was conjugated to rat-anti-mouse-IgG1-dyna-
beads (diameter 4.5 μ m, Invitrogen, Karlsruhe, Ger-
many) according to the manufacturer’s instructions.
For Immunomagnetic labeling of CEC the EDTA
blood sample was diluted 1:1: with PEB buffer (phos-
phate buffered saline, PBS, pH 7.4 (Invitrogen), 0.01%
bovine serum albumin, BSA (PAA, Cölbe, Germany), 10
mM ethylene-diamine-tetra-acetic acid, EDTA (Carl
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blocker (Miltenyi Biotec, Bergisch-Gladbach, Germany)
to prevent unspecific leukocyte binding, and 100 μ l
CD146-coupled dynabeads. Samples were incubated on
a rotator (10 rpm) for one hour at 4°C. Immunomagne-
tically labeled cells were isolated in a specific magnetic
separator (Dynal MPC-L, Invitrogen). After washing
thrice with PEB the isolated cells were resuspended in
90 μ l PEB + 10 μ l fluorescein-labeled Ulex-europaeus-
agglutenin-1 (UEA-1, Vector Laboratories, Burlingame,
CA, USA) and incubated for 1 h on a shaker (300 rpm)
at 4°C in the dark. After three wash cycles in PEB the
cells were resuspended in 200 μ l PEB. CEC were identi-
fied and enumerated in 50 μ l samples independently by
three blinded observers using an inverted fluorescence
microscope (Ti-U equipped with a DS-Qi1MC camera,
Nikon, Düsseldorf, Germany) at 20x magnification,
phase contrast, 10% transmission light and fluorescein
excitation.
Criteria defining a CEC [18] were:
1. fluorescein positive
2. 15-30 μ m diameter of cell body and
3. bound to at least 4 dynabeads.
The total number of CEC was normalized to a volume
of one ml of peripheral blood
3. Serology
Serological evaluation of patients’ blood was performed
at six different time points perioperatively (Figure 2)
according to standard hospital protocols including car-
diac enzymes creatinin kinase (CK), CK-MB, Troponin
T and neuron-specific enolase (NSE). Additionally, von-
Willebrand factor antigen (vWF) was measured by
immunoturbidimetric determination using the Dade
B e h r i n gv W F : A gt e s tk i t( D a d eB e h r i n gM a r b u r g
GmbH, Marburg, Germany). For determination of solu-
ble thrombomoduline concentration (sTM, CD 141), a
commercial solid phase sandwich enzyme-linked
immunsorbent assay kit was used (human sCG141
ELISA kit. Diaclone Research, Besancon, France).
4. Hemodynamic evaluation
All patients were monitored by invasive hemodynamic
assessment using a pulmonary artery catheter. Data col-
lection was performed at 7 different time points perio-
peratively (Figure 2).
5. Statistical Analysis
All data were stored and analyzed using the SPSS statis-
tical package 17.0 (SPSS Inc., Chicago, Ill., USA).
Descriptive statistics were computed for variables of
interest and analyzed using univariate ANOVA. Contin-
uous data were analyzed using ANOVA with repeated
Figure 1 Separation of circulating endothelial cells. EDTA blood was incubated with anti-CD146 labelled dynabeads, circulating endothelial
cells were magnetically separated and quantified by fluorescence microscopy.
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0.05.
Results
Patients’ perioperative demographics are summarized in
Table 1. There was no statistical difference between
both experimental groups regarding age, gender, weight
and Euro-Score. Generally, no mortality, perioperative
stroke or ST-elevation myocardial infarct was observed
during the entire study period. Operation time was sig-
nificantly longer in the Mini-HLM group (179 ± 34
minutes vs. 141 ± 34 minutes), however perioperative
Figure 2 Schedule of data collection. Serial evaluation of hemodynamics and serological parameters with regard to hospital stay.
Table 1 Patients’ demographics and perioperative data
Mini-HLM OPCAB p-Wert
Age (yrs) 65,6 ± 11,2 64,7 ± 10,9 0,723
Heigh (cm) 173 ± 7 168 ± 8 0,307
Weight (kg) 85,1 ± 12,1 83,7 ± 14,6 0,673




Transitory psychotic disorder syndrome 2/42 (4,7%) 1/34 (2,9%) 0,197
Postoperative atrial fibrillation 16/42 (38,1%) 14/34 (41,2%) 0.817
Operation time (minutes) 174,6 ± 33,4 138,9 ± 32,9 < 0.001
LIMA +RIMA usage 11/42 (26,2%) 6/34 (17,6%) 0.419
Intensive care stay (days) 2,55 ± 0,97 2,18 ± 7,3 0,075
Chest tube drainage (48 hours) 1204 ± 600 1040 ± 412 0,187
Ventilation time (hours) 16,3 ± 10,0 13,2 ± 3,9 0,101
Transfusion of Red Blood Cells postoperatively 1,45 ± 1,96 0,81 ± 1,31 0,119
Transfusion of thrombocytes postoperatively 0,35 ± 0,74 0,16 ± 0,45 0,195
Transfusion of Fresh Frozen Plasma postoperatively 0,75 ± 2,1 0,56 ± 1,4 0,65
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order syndromes was equally low distributed between
groups. Operative usage of bilateral internal mammry
artery grafts did not show any significant differences,
and overall chest tube drainage, ventilation time, trans-
fusion requirements and total intensive care stay were
comparable in both cohorts. Serial assessment of
patients’ hemodynamics did nor show any differences in
cardiac index (p = 0.504, Figure 3).
Circulating Endothelial Cells
Preoperative CEC numbers (cells per milliliter of blood)
did not differ between the experimental groups (Mini-
HLM: 7,39 ± 9,94; OPCAB: 7,03 ± 12,54; p = 0.901). 60
minutes after arrival on the ICU, CEC values peaked in
both groups and decreased over time until postoperative
day 5, where the preoperative niveau was reached (Fig-
ure 4). Statistical analysis did not reveal any significant
differences regarding the CEC kinetics between both
groups (p = 0.274).
Serology
Serial evaluation of troponin T values (Figure 5, p =
0.108) and NSE did not show any significant differences
between Mini-HLM and OPCAB operated patients
according to the clinical results of freedom from STEMI
and incidence of transitory psychotic disorder syndrome.
Furthermore, kinetics of soluble thrombomodulin (p =
0.102, Figure 6) and von Willebrand factor antigen did
not show any significant differences.
Vessel disease and graft number
According to the preoperative angiograms, the degree of
vessel disease was equally distributed between groups,
and a mean number of 2.72 ± 0.52 grafts was preopera-
tively planned in Mini-HLM patients in contrast to 2.47
± 0.84 grafts in OPCAB patients (p = 0.204). Intraopera-
tively, however, the actual graft number (Figure 7) was
significantly higher in the Mini-HLM group (3.06 ±
0.72) as compared to OPCAB operated patients (1.89 ±
0.74, p < 0.01) indicating a more complete revasculariza-
tion in the Mini-HLM group.
Comment
Cardiac surgery performed with CCPB may lead to ser-
ious complications in up to 20% of low-risk patients
[19]. More than two decades ago, Kirklin et al. [1]
reported complement activation following CCPB which
triggers a whole body defense reaction which may lead
to significant alterations of cerebral function and mul-
tiple other harmful effects. After introduction of the
minimally invasive direct coronary artery bypass (MID-
CAB) procedure for treatment of single vessel (LAD)
disease [20], the evolution of that promising off-pump
approach approach let to the interdisciplinary multives-
sel “hybrid procedure” with MIDCAB-grafting of the
LAD culprit lesion followed by interventional stenting
of remaining coronary lesions [21]. However, long-term
Figure 3 Invasive hemodynamics: perioperative cardiac index.
Serial time couse of cardiac index measured by pulmonary artery
catheter in patients operated by use of Mini-HLM (blue line) or by
OPCAB techniques (red line); Significance level: p = 0.504.
Figure 4 Perioperative numbers of Circulating Endothelial Cells
(CEC, corrected for hematocrit). Serial time couse of CEC in
patients operated by use of Mini-HLM (blue line) or by OPCAB
techniques (red line); Significance level: p = 0.274.
Figure 5 Cardiax enzymes perioperatively: Troponin T.S e r i a l
time couse of Troponin T in patients operated by use of Mini-HLM
(blue line) or by OPCAB techniques (red line); Significance level: p =
0.108.
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known restenosis rates of stented areas [22]. The com-
plete surgical multivessel revascularization on the beat-
ing heart (OPCAB) was introduced in the mid-1990’s
[2] and is a safe and well-established technique.
Patients who undergo coronary surgery with this strat-
e g yw e r ei n i t i a l l ys h o w nt oh a v eal o w e ri n c i d e n c eo f
postoperative complications and remarkable advantages
in terms of hospital stay [23]. However, although there
was a significantly lower deterioration in psychometric
tests in OPCAB patients in the early postoperative
course as compared to CCPB patients [24], this advan-
tage of the OPCAB technique has resolved with respect
to the 5-year cognitive and cardiac outcomes [25].
Furthermore, complete coronary revascularization may
not be achievable in all patients by off-pump techni-
ques owing to the complex anatomy of coronary
lesions and the possibility of hemodynamic instability
while the beating heart is manipulated [4]. Interest-
ingly, recent studies show inferior long-term patency
rates and incompleteness of revascularization with
regard to OBCAB-techniques [26,27]. In the recently
published ROOBY trial [28], especially the lower
patency rate of saphenous vein grafts in the OPCAB
group accounted for the observed differences in graft
function. However, with special attention to the prog-
nostically important left internal thoracic artery grafts
to the LAD culprit lesions, it could be shown that -
with classification of those grafts according to the
established FitzGibbon grade [29] - there were signifi-
cantly fewer grade A grafts in the OPCAB group than
in the cardiopulmonary bypass group indicating lower
quality of graft anastomoses. As a consequence, multi-
ple efforts were taken to achieve the same advantages
with modified cardiopulmonary bypass systems as can
be achieved with OPCAB approaches. The solution was
miniaturization of CBP-systems thus resulting in
reduction of foreign surfaces, avoidance of blood-air
contact and significant reduction of priming volume.
The advantages of such minimized systems have been
shown in several clinical studies so far [30,31]. Overall
experience indicates an inferior biocompatibility of
CCPB compared to Mini-HLM [32] which is consid-
ered to be caused by contact activation of blood cells
with artificial surfaces and air, the ischemia and reper-
fusion injury and hemodilution. Furthermore, the
endoxemia caused by intestinal hypoperfusion repre-
sents a predominant trigger of complement activation
and profound endothelial damage [33]. In this context,
a modern approach for assessing endothelial integrity
includes the determination of circulating endothelial
cells (CEC) in the peripheral blood. CEC are defined as
mature endothelial cells in the peripheral blood,
detached from vessel walls as a result of injury via
mechanical strain or disease or inflammation via para-
crine or endocrine factors. The correlation of CEC and
cardiovascular disease and its implications have
recently been reviewed extensively [34]. Under physio-
logic conditions, CEC occur in humans in the range of
5-10 cells per ml blood, whereas elevated numbers are
found in patients with different vascular disorders and
type 2 diabetes mellitus [35,36]. The detachment of
endothelial cells into the blood stream represents a ser-
ious injury of the endothelium as one of multiple
severe adverse effects of CCPB [1,11], and overall CEC
values are significantly lower in OPCAB patients when
compared to standard cardiopulmonary bypass proce-
dures [37]. CEC do not only unveil endothelial damage
but also correlate with activity and degree of endothe-
lial injury [12]. Therefore, CEC are considered to
represent a novel marker of the intrinsic endothelial
damage caused by CCPB, and use of modern Mini-
HLM systems were found to be associated with signifi-
cantly reduced CEC release as compared to CCPB [11].
Figure 6 Serology perioperatively: soluble thrombomodulin
(sTM, CD141). Serial time couse of sTM in patients operated by use
of Mini-HLM (blue line) or by OPCAB techniques (red line);
Significance level: p = 0.102.
Figure 7 Coronary artery bypass grafts. Number of bypass grafts
actually performed in Mini-HLM group (blue) or OPCAB group (red).
Significance level: p < 0.001.
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Mini-HLM approach by means of the ROCSafe™ sys-
tem can achieve overall clinical results that are comple-
tely comparable to those of OPCAB revascularisation.
Although non-elective patients and patients with insu-
lin-dependent diabetes mellitus had to be excluded from
the study as unstable angina and/or acute myocardial
infarction as well as diabetes per se significantly increase
CEC numbers [17], no further restrictions were imposed
with regard to enrollment, and the study patients there-
fore represent an institution-based cohort of routine
coronary surgical practice. As the development of mod-
ern and risk-adjusted concepts for complete and safe
revascularization in coronary patients is one of the main
goals in coronary surgery, use of Mini-HLM and thus
minimizing the side effects of CCPB is a desirable mod-
ern approach. In today’s economically affected health
care systems, this conclusion is especially important as
OPCAB procedures are associated with longer hospital
stays and greater overall hospitalization costs in signifi-
cant dimensions [38]. Increasingly, the referring cardiol-
ogists or the patients themselves insist on an OPCAB
procedure. The medical decision to apply the OPCAB
technique in these patients is a delicate balance between
handling the pressure to compete for more CABG cases
and providing sound surgical care [38]. Therefore, per-
forming OPCAB in every single patient who seems to
be a candidate for surgical myocardial revascularisation
for the sole purpose of attracting more patients or due
to other political and economic pressures may not be
appropriate and economically hazardous [38]. With
regard to the increasing overall excellent experience
with Mini-HLM worldwide [39,40], OPCAB should be
restricted to carefully selected special cases, i.e. patients
presenting with severely calcified aorta etc..
The described results should be considered provisional
and worthy of further investigation in larger studies,
because the relatively small sample size might represent
a limitation to our conclusions. However, the major
finding of the present investigation is the fact that CEC
release and, thus, endothelial damage, is completely
comparable between Mini-HLM procedures and the
OPCAB technique.
Conclusion
Conceptional advantages of the closed minimized CPB-
system ROCsafe™ result in morbidity and mortality
comparable with OPCAB procedures. Mini-HLM, there-
fore, minimizes CPB-related systemic and organ injury
as demonstrated by low CEC-values which indicates
intact endothelial integrity. Furthermore, Mini-HLM
combines OPCAB-benefits with less morbidity in high-
risk-patients while facilitating more complete revascular-
isation in patients with complex lesions. Mini-HLM
should therefore be applied as a routine and gold stan-
dard technique in coronary artery bypass surgery.
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